Clive A. Prestidge is currently a Professor of Clinical and Health Science, a lead researcher at UniSA's Cancer Research Institute, and head of the Nanostructure and Drug Delivery research group. Clive is the author of more than 250 refereed international journal articles, textbook chapters and conference papers and more than 100 major project reports to industry. He has taken a leadership role in a number of major collaborative projects in association with national and international industries, the ARC, and University researchers from Australia and overseas. Clive has attracted competitive research grants worth more than $15M from government and industry sources. Clive was the founder of Ceridia Pty Ltd, a clinical-stage biopharmaceutical company established to commercialize the Lipoceramic drug delivery technology he invented. The Prestidge research group is focused on Drug delivery, Nanomedicine and BioPharmaceutical Engineering. Its Primary Mission is to: (1) engineer novel particle-based biomaterials with specific biological activities and to apply them to solve biopharmaceutical challenges; (2) determine mechanisms for bioactivity through advanced biophysical analyses; and (3) develop drug delivery solutions to address unmet clinical needs. Some of our overarching challenges are to: (1) deliver challenging therapeutic molecules for better medicines; (2) eradicate bacterial biofilms; and (3) optimize biotech and pharmaceutical processing and manufacturing.